A review of two studies demonstrating that large-scale pooled base editor screens can separate pathogenic from benign mutations and identify variants that are associated with altered cellular growth or response to DNA-damaging agents.
25 result(s)
A summary of a recent publication in The Journal of Biotechniques showing the utility of Horizon's synthetic sgRNA for CRISPR mediated transcriptional activation studies.
Here we discuss a recent paper by Gisela Jimenez-Duran and colleagues highlighting how a whole genome CRISPR knockout screen, carried out by Horizon Discovery, has enabled identification of a pre-existing inhibitor that can regulate pro-inflammatory macrophages.
Thinking about doing CRISPR screening for knock out, CRISPR activation or CRISPRi applications? Unsure whether a synthetic arrayed or pooled lentiviral screening library is best for your project? We are here to help.
A summary of a recent publication in The CRISPR Journal showing that Horizon's integrated pooled CRISPRko and high throughput cell panel screening platform together offer clinically relevant information for therapeutic targets.
Here we talk about the role of the Edit-R Pooled sgRNA Indexing PCR Primers and answer the most common questions about the Indexing PCR and Sequencing Primer kit.
Demonstration of a repeatable pooled lentiviral sgRNA screen in primary human T cells
Achieve DNA-free guaranteed gene editing with synthetic predesigned sgRNA reagents and libraries covering the entire human genome.
Choosing the right cell-based screen from the plethora of options available can quickly become a complicated decision process. Here, we review two of the major options: cell panel and functional genomic screening.
The clinical success rate of new oncology drugs is only 3.4% compared to 20.9% in other disease types (Wong et al, 2018). One contributing factor to this issue is the testing systems used, with two-dimensional (2D) monolayer assay formats as the traditional mainstay of high throughput screening. Although 2D monolayer assays have identified many successful drugs, it is increasingly recognized that they do not accurately model key aspects of the three-dimensional (3D) tumor environment. Therefore, the adoption of high throughput screening approaches using 3D assays to complement 2D approaches could substantially improve prediction of clinical outcomes and reduce the high failure rate of cancer drugs in clinical trials.